Biogen Inc(BIIB) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 4:39 PM ET (Korea 10/29 05:39)
Full metrics table
| Index | S&P 500 | P/E | 43.22 | EPS (ttm) | 5.65 | Insider Own | 0.75% | Shs Outstand | 147.7M | Perf Week | 1.27% |
| Market Cap | 36.06B | Forward P/E | 14.82 | EPS next Y | 33.09% | Insider Trans | -0.11% | Shs Float | 146.6M | Perf Month | 7.48% |
| Enterprise Value | 43.13B | PEG | 2.13 | EPS next Q | 3 | Inst Own | 98.78% | Short Float | 3.75% | Perf Quarter | 17.37% |
| Income | 0.83B | P/S | 3.73 | EPS this Y | -19% | Inst Trans | 3.09% | Short Ratio | 5.26 | Perf Half Y | 25.55% |
| Sales | 9.66B | P/B | 1.91 | EPS next 5Y | 6.94% | ROA | 2.76% | Short Interest | 5.50M | Perf YTD | 38.67% |
| Book/sh | 127.61 | P/C | 28.06 | EPS past 3/5Y | -25.04% -18.74% | ROE | 4.58% | 52W High | -4.07% ($254.41) | Perf Year | 63.65% |
| Cash/sh | 8.7 | P/FCF | 13.37 | Sales past 3/5Y | 0.35% -5.06% | ROIC | 3.16% | 52W Low | 76.85% ($138.00) | Perf 3Y | 4.06% |
| Dividend Est. | - | EV/EBITDA | 15.82 | EPS Y/Y TTM | -45.79% | Gross Margin | 64.29% | Volatility(W/M) | 3.81% 2.94% | Perf 5Y | -7.86% |
| Dividend TTM | - | EV/Sales | 4.46 | Sales Y/Y TTM | 0.53% | Oper. Margin | 19.5% | ATR (14) | 7.35 | Perf 10Y | -6.59% |
| Dividend Ex-Date | - | Quick Ratio | 1.26 | EPS Q/Q | -84.85% | Profit Margin | 8.64% | RSI (14) | 59.84 | Recom | 1.84 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.87 | Sales Q/Q | 2.38% | SMA20 | 4.17% ($234.28) | Beta | 0.12 | Target Price | $258.93 |
| Payout | - | Debt/Eq | 0.44 | Earnings | 2026/10/28 | SMA50 | 8.12% ($225.72) | Rel Volume | 2.38 | Prev Close | $252.73 |
| Employees | 7500 | LT Debt/Eq | 0.4 | EPS/Sales Surpr. | 31.53% 6.43% | SMA200 | 21.78% ($200.4) | Avg Volume(3M) | 1.05M | Price | $244.05 |
| IPO | 1991/9/17 | Option/Short | Yes/Yes | Trades | 34314 | Volume | 2,493,009 | Change | -3.43% |
🧠 This is a global pharmaceutical company specializing in the development of treatments for multiple sclerosis, Alzheimer's disease, and rare neurological disorders. Leveraging its long-accumulated R&D capabilities and biopharmaceutical manufacturing expertise, the company has built a strong position in the field of neurological diseases.
Over the past 1 year, on the higher side
4% below its 1-year high.
Traded more than usual. That is 238% of its average volume.
BIIB earns at a steady pace
Of every $100 in sales, $19.50 is kept as operating profit.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -19.0% this year.
Tap to view numbers
The price is about the industry average
Counting its debt, for $100 of yearly operating cash you would pay $1,582. Peers typically go for $1,458. Compared with its own 5-year average, it is 49% pricier now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -7.9%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 98.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #14 of 21 in the industry
Based on market cap of $36B.
FAQ
What kind of company is BIIB?
BIIB belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.
What is the market cap of BIIB?
The market cap of BIIB is approximately $36.1B, ranking 413 within its sector.
What is the P/E ratio of BIIB?
BIIB has a P/E ratio of approximately 43.2x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for BIIB?
BIIB has recorded a 52-week high of $254.41 and a low of $138.00.
